PW Medtech Group Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de PW Medtech Group.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	40.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

PW Medtech Group's (HKG:1358) Solid Earnings Are Supported By Other Strong Factors

Sep 26

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

Feb 18

Should You Rely On PW Medtech Group's (HKG:1358) Earnings Growth?

Jan 23

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Dec 28

Should You Be Adding PW Medtech Group (HKG:1358) To Your Watchlist Today?

Dec 10

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Nov 22

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como PW Medtech Group no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SEHK:1358 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	694	152	201	270	N/A
3/31/2024	685	153	165	240	N/A
12/31/2023	675	153	129	211	N/A
9/30/2023	658	135	135	208	N/A
6/30/2023	642	116	142	204	N/A
3/31/2023	589	111	175	237	N/A
12/31/2022	537	106	207	269	N/A
9/30/2022	444	72	154	202	N/A
6/30/2022	352	39	100	135	N/A
3/31/2022	312	389	63	86	N/A
12/31/2021	271	739	26	37	N/A
9/30/2021	275	995	49	61	N/A
6/30/2021	279	1,252	72	86	N/A
3/31/2021	263	942	71	82	N/A
12/31/2020	247	632	70	78	N/A
9/30/2020	269	398	81	98	N/A
6/30/2020	291	163	92	118	N/A
3/31/2020	327	123	72	109	N/A
12/31/2019	362	82	53	100	N/A
6/30/2019	340	136	-2	83	N/A
3/31/2019	325	126	-14	90	N/A
12/31/2018	311	115	-26	98	N/A
6/30/2018	300	27	-21	158	N/A
3/31/2018	293	16	N/A	171	N/A
12/31/2017	287	5	N/A	184	N/A
9/30/2017	236	11	N/A	N/A	N/A
6/30/2017	185	17	N/A	209	N/A
3/31/2017	252	63	N/A	238	N/A
12/31/2016	320	109	N/A	267	N/A
6/30/2016	455	197	N/A	289	N/A
3/31/2016	485	201	N/A	274	N/A
12/31/2015	516	204	N/A	260	N/A
9/30/2015	650	208	N/A	211	N/A
6/30/2015	665	208	N/A	162	N/A
3/31/2015	637	192	N/A	124	N/A
12/31/2014	608	177	N/A	86	N/A
9/30/2014	557	144	N/A	61	N/A
6/30/2014	507	112	N/A	36	N/A
3/31/2014	482	95	N/A	44	N/A
12/31/2013	457	78	N/A	53	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 1358 es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 1358 crezcan más rápidamente que el mercado Hong Kong

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 1358 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 1358 crezcan más rápidamente que el mercado de Hong Kong.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 1358 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 1358 se prevé que sea elevada dentro de 3 años.

PW Medtech Group Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

PW Medtech Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

PW Medtech Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Recent updates

Upcoming dividend of HK$0.045 per share

PW Medtech Group's (HKG:1358) Solid Earnings Are Supported By Other Strong Factors

Insufficient new directors

PW Medtech Group Limited to Report First Half, 2024 Results on Aug 30, 2024

Now 21% overvalued after recent price rise

Upcoming dividend of HK$0.05 per share

Executive Chairman & CEO recently sold HK$53k worth of stock

Here's Why PW Medtech Group Limited's (HKG:1358) CEO Might See A Pay Rise Soon

PW Medtech Group Limited (SEHK:1358) announces an Equity Buyback for HKD 150 million worth of its shares.

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: EPS: CN¥0.098 (vs CN¥0.068 in FY 2022)

PW Medtech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

There's Reason For Concern Over PW Medtech Group Limited's (HKG:1358) Price

Upcoming dividend of HK$0.049 per share at 11% yield

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

PW Medtech Group Limited to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Market cap size

Full year 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.47 in FY 2021)

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

First half 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.48 in 1H 2021)

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

PW Medtech Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited (SEHK:1358) agreed to acquire 51.5% stake in Beijing Ruijian High-Tech Biological Technology Co., Ltd from a group of shareholders for CNY 412 million.

First half 2021 earnings released: EPS CN¥0.48 (vs CN¥0.09 in 1H 2020)

Investor sentiment improved over the past week

Independent Non-Executive Director Xingdong Zhang has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

PW Medtech Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

New 90-day low: HK$0.52

Should You Rely On PW Medtech Group's (HKG:1358) Earnings Growth?

New 90-day high: HK$2.31

CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358).

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Should You Be Adding PW Medtech Group (HKG:1358) To Your Watchlist Today?

New 90-day high: HK$2.29

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Market bids up stock over the past week

CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358) for approximately $110 million.

New 90-day high: HK$1.76

First half earnings released

PW Medtech Group Limited to Report First Half, 2020 Results on Aug 27, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento